Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
The relationship between statin-induced increases in HDL cholesterol (HDL-C) concentration and statin-induced decreases in LDL cholesterol (LDL-C) is unknown. The effects of different statins on HDL-C levels, relationships between changes in HDL-C and changes in LDL-C, and predictors of statin-induced increases in HDL-C have been investigated in an individual patient meta-analysis of 32,258 dyslipidemic patients included in 37 randomized studies using rosuvastatin, atorvastatin, and simvastatin. The HDL-C raising ability of rosuvastatin, and simvastatin was comparable, with both being superior to atorvastatin. Increases in HDL-C were positively related to statin dose with rosuvastatin and simvastatin but inversely related to dose with atorvastatin. There was no apparent relationship between reduction in LDL-C and increase in HDL-C, whether analyzed overall for all statins (correlation coefficient = 0.005) or for each statin individually. Percentage increase in apolipoprotein A-I was virtually identical to that of HDL-C at all doses of the three statins. Baseline concentrations of HDL-C and triglyceride (TG) and presence of diabetes were strong, independent predictors of statin-induced elevations of HDL-C. Statins vary in their HDL-C raising ability. The HDL-C increase achieved by all three statins was independent of LDL-C decrease. However, baseline HDL-C and TGs and the presence of diabetes were predictors of statin-induced increases in HDL-C.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Statins also elevate high-density lipoprotein cholesterol (HDL-C) in a dose-dependent manner by up to + 10% [32].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [32]
In the citing paper
“Moreover, the long-term safety of the regular consumption of these products has not been fully documented and safety issues due to the possible presence of contaminants in some preparations have been raised.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [185]
In the citing paper
“Different commercial preparations of RYR have different concentrations of monacolins, and lower TC and LDL-C levels to variable extents, but the consumer is not able to make that distinction [144,185].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [185]
In the citing paper
“Hypocholesterolaemic effects of RYR are related to a statin-like mechanism-inhibition of hydroxymethylglutaryl-coenzyme A (HMGCoA) reductase-of monacolins, which represent the bioactive ingredient.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [185]
In the citing paper
“In a meta-analysis 291 of several intervention studies in dyslipidaemic patients, elevations in HDL-C varied with dose among the respective statins; such elevations were typically in the range of 5-10%.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [291]
Citations
Cites
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000344393.60303.0a · Cited by 3,641
Jones, P. H., Davidson, M. H., Stein, E. A., Bays, H. E., McKenney, J. M., Miller, E., Cain, V. A., & Blasetto, J. W. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00530-7 · Cited by 1,398
Diabetes and atherosclerosis: An epidemiologic view
Pyörälä, K., Laakso, M., & Uusitupa, M. (1987) · Diabetes/Metabolism Reviews · doi:10.1002/dmr.5610030206 · Cited by 919
Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis
Nicholls, S. J., Tuzcu, E. M., Sipahi, I., Grasso, A. W., Schoenhagen, P., Hu, T., Wolski, K., Crowe, T., Desai, M. Y., Hazen, S. L., et al. (2007) · JAMA · doi:10.1001/jama.297.5.499 · Cited by 724
Self-citationPedersen, T. R., Olsson, A. G., Færgeman, O., Kjekshus, J., Wedel, H., Berg, K., Wilhelmsen, L., Haghfelt, T., Thorgeirsson, G., Pyörälä, K., et al. (1998) · Circulation · doi:10.1161/01.cir.97.15.1453 · Cited by 621
Rubins, H. B. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.22.2597 · Cited by 586
Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia
Davidson, M. H., McGarry, T., Bettis, R., Melani, L., Lipka, L. J., LeBeaut, A. P., Suresh, R., Sun, S., & Veltri, E. P. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02610-4 · Cited by 558
Cited by
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
Effect of Two Intensive Statin Regimens on Progression of Coronary Disease
Nicholls, S. J., Ballantyne, C. M., Barter, P. J., Chapman, M. J., Erbel, R. M., Libby, P., Raichlen, J. S., Uno, K., Borgman, M., Wolski, K., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1110874 · Cited by 890
Self-citationESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.028 · Cited by 706
Duan, Y., Gong, K., Xu, S., Zhang, F., Meng, X., & Han, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01125-5 · Cited by 538
“Statins have been reported to elevate HDL-C, which also varies with dose among different statins.(220) However, when LDL-C is below a certain level, statinelevated HDL-C has little effect on disease regression.”
BackgroundRosenson, R. S., Brewer, H. B., Chapman, M. J., Fazio, S., Hussain, M. M., Kontush, A., Krauss, R. M., Otvos, J. D., Remaley, A. T., & Schaefer, E. J. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2010.155333 · Cited by 511
HDL-targeted therapies: progress, failures and future
Kingwell, B. A., Chapman, M. J., Kontush, A., & Miller, N. E. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4279 · Cited by 354
Sterol metabolism and SREBP activation
Sato, R. (2010) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2010.06.004 · Cited by 295
Ali, K. M., Wonnerth, A., Huber, K., & Wojta, J. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02081.x · Cited by 292
“Referring to results from the VOYAGER meta-analysis, saying that the extent of HDL-C increase is dependent on HDL-C levels at baseline (low HDL-C levels are associated with a higher increase during statin treatment) the observations made in JUPITER could therefore lead to false conclusions (Barter et al., 2010).”
BackgroundResultInfluentialBergheanu, S. C., Bodde, M. C., & Jukema, J. W. (2017) · Netherlands Heart Journal · doi:10.1007/s12471-017-0959-2 · Cited by 282
“Statins Statins produce elevations in HDL-C levels between 5–10% [32].”
BackgroundNiacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk
Chapman, M. J., Redfern, J. S., McGovern, M. E., & Giral, P. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.01.008 · Cited by 227
The LDL-HDL Profile Determines the Risk of Atherosclerosis: A Mathematical Model
Hao, W., & Friedman, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090497 · Cited by 219
“specify what levels of LDL are low risk and what levels are high risk; they also specify what levels of HDL are poor and what levels are near ideal [24,25].”
BackgroundWang, H., Ni, X., Qing, X., Zeng, D., Luo, M., Liu, L., Li, G., Pan, K., & Jing, B. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.01073 · Cited by 160
Ray, K. K., Stoekenbroek, R. M., Kallend, D., Leiter, L. A., Landmesser, U., Wright, R. S., Wijngaard, P., & Kastelein, J. J. P. (2018) · Circulation · doi:10.1161/circulationaha.118.034710 · Cited by 154
Beyond Lipid-Lowering: Effects of Statins on Cardiovascular and Cerebrovascular Diseases and Cancer
Morofuji, Y., Nakagawa, S., Ujifuku, K., Fujimoto, T., Otsuka, K., Niwa, M., & Tsutsumi, K. (2022) · Pharmaceuticals · doi:10.3390/ph15020151 · Cited by 151
“by using statins, the rate of HDL-C increase has been shown to be less than 10%, but the rate of ApoB-containing protein decrease has been large, and it is possible that the HDL-C increase is involved in these results [47].”
ResultSaku, K., Zhang, B., Noda, K., & The PATROL Trial Investigators (2011) · Circulation Journal · doi:10.1253/circj.cj-10-1281 · Cited by 128
High-density lipoprotein cholesterol, coronary artery disease, and cardiovascular mortality
Silbernagel, G., Schottker, B., Appelbaum, S., Scharnagl, H., Kleber, M. E., Grammer, T. B., Ritsch, A., Mons, U., Holleczek, B., Goliasch, G., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht343 · Cited by 123
“Therefore, we were not able to adjust for possible moderate fluctuations of HDL cholesterol during the follow-up, for example due to the start of statin treatment or an increase of the statin dose.(28) The major strength of this work is the detailed clinical and metabolic investigation of the LURIC participants, inclu…”
BackgroundThe Effect of Testosterone on Cardiovascular Biomarkers in the Testosterone Trials
Mohler, E. R., Ellenberg, S. S., Lewis, C. E., Wenger, N. K., Budoff, M. J., Lewis, M. R., Barrett-Connor, E., Swerdloff, R. S., Stephens-Shields, A., Bhasin, S., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02243 · Cited by 116
The pharmacological management of metabolic syndrome
Rask Larsen, J., Dima, L., Correll, C. U., & Manu, P. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1429910 · Cited by 113
“effect relationship varies as well, as it appears to be linear for rosuvastatin and simvastatin, but not for atorvastatin [75].”
BackgroundDiscovery of drug-omics associations in type 2 diabetes with generative deep-learning models
Allesøe, R. L., Lundgaard, A. T., Hernández Medina, R., Aguayo-Orozco, A., Johansen, J., Nissen, J. N., Brorsson, C., Mazzoni, G., Niu, L., Biel, J. H., et al. (2023) · Nature Biotechnology · doi:10.1038/s41587-022-01520-x · Cited by 111
HDL-C: Role as a risk modifier
Barter, P. J. (2011) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(11)70885-6 · Cited by 135
Self-citationEstablished and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention
Michaeli, D. T., Michaeli, J. C., Albers, S., Boch, T., & Michaeli, T. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00594-5 · Cited by 109
“Statins also elevate high-density lipoprotein cholesterol (HDL-C) in a dose-dependent manner by up to + 10% [32].”
BackgroundMolecular Mechanisms of HDL-Cholesterol Elevation by Statins and Its Effects on HDL Functions
Yamashita, S., Tsubakio‐Yamamoto, K., Ohama, T., Nakagawa-Toyama, Y., & Nishida, M. (2010) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.5405 · Cited by 114
Beginning to Understand High-Density Lipoproteins
Santos‐Gallego, C. G., Badimon, J. J., & Rosenson, R. S. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2014.08.001 · Cited by 100
“9%.(122) This effect did not correlate with the effect size of the LDL-C reduction.”
BackgroundHDL and Reverse Remnant-Cholesterol Transport (RRT): Relevance to Cardiovascular Disease
Kontush, A. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.07.005 · Cited by 101
Statins—From Fungi to Pharmacy
Sadowska, A. J., Osiński, P., Roztocka, A., Kaczmarz-Chojnacka, K., Zapora, E., Sawicka, D., & Car, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010466 · Cited by 92
“…[27] ↓ 46–50%—40 mg/day [27] ↓ 50–55%—80 mg/day [27] ↓ 37.1%—51.7%— 10–80 mg/day [88] ↓ 36% to 53%— 10–80 mg/day [89] ↑ 8%—10 mg/day [87] ↑ 4.5%—10 mg [81] Falling to 2.3%—80 mg [81] ↓ 20%—10 mg/day [90] ↓ 22.6%—20 mg/day [90] ↓ 26.8%—40 mg/day [90] Taking a statin at any time of the day [91].”
InfluentialEffect of vildagliptin and pravastatin combination on cholesterol efflux in adipocytes
Mostafa, A. M., Hamdy, N. Μ., Abdel‐Rahman, S. Z., & EL-Mesallamy, H. O. (2016) · IUBMB Life · doi:10.1002/iub.1510 · Cited by 85
“The use of statins has revolutionized the management of patients at risk of having a cardiovascular event (6).”
BackgroundKerr, G., Aujero, M., Richards, J., Sayles, H., Davis, L., Cannon, G., Caplan, L., Michaud, K., & Mikuls, T. (2014) · Arthritis Care & Research · doi:10.1002/acr.22341 · Cited by 72
The Causes and Consequences of Low Levels of High Density Lipoproteins in Patients with Diabetes
Barter, P. J. (2011) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2011.35.2.101 · Cited by 82
Self-citationMeikle, P. J., Wong, G., Tan, R., Giral, P., Robillard, P., Orsoni, A., Hounslow, N., Magliano, D. J., Shaw, J. E., Curran, J. E., et al. (2015) · Journal of Lipid Research · doi:10.1194/jlr.p061143 · Cited by 65
How to control residual cardiovascular risk despite statin treatment: Focusing on HDL–cholesterol
Lim, S. K., Park, Y. M., Sakuma, I., & Koh, K. K. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.03.127 · Cited by 69
“on simvastatin, atorvastatin and rosuvastatin, showed that HDL–C increases with simvastatin and rosuvastatin were superior to those seen with atorvastatin [48].”
BackgroundGao, M., Zhao, D., Schouteden, S., Sorci‐Thomas, M. G., Veldhoven, P. P. V., Eggermont, K., Liu, C., Verfaillie, C. M., & Feng, Y. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.304006 · Cited by 69
Lipid lowering therapy in cardiovascular disease: From myth to molecular reality
Mourikis, P., Zako, S., Dannenberg, L., Nia, A. M., Heinen, Y., Busch, L., Richter, H., Hohlfeld, T., Zeus, T., Kelm, M., et al. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107592 · Cited by 63
Alterations of Lipid Profile in COVID-19: A Narrative Review
Rezaei, A., Neshat, S., & Heshmat‐Ghahdarijani, K. (2021) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2021.100907 · Cited by 64
Pitavastatin in cardiometabolic disease: therapeutic profile
Masana, L. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-s1-s2 · Cited by 59
“Moreover, studies have shown that increasing HDL-C levels using statins can signifi cantly reduce the progression of atherosclerosis and reduce CV and cerebrovascular risk in people with dyslipidemia irrespective of LDL-C levels [35-39].”
BackgroundEgom, E. E. A., & Hafeez, H. (2016) · Advances in clinical chemistry · doi:10.1016/bs.acc.2015.10.005 · Cited by 74
Combination therapy in dyslipidemia: Where are we now?
Catapano, A. L., Farnier, M., Foody, J. M., Toth, P. P., Tomassini, J. E., Brudi, P., & Tershakovec, A. M. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.09.026 · Cited by 55
“5% [37].”
Nicholls, S. J., Borgman, M., Nissen, S. E., Raichlen, J. S., Ballantyne, C. M., Barter, P. J., Chapman, M. J., Erbel, R. M., & Libby, P. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.570746 · Cited by 62
Self-citationAntioxidant Effects of Statins in the Management of Cardiometabolic Disorders
Lim, S. K., & Barter, P. J. (2014) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.24398 · Cited by 54
Self-citationWood, G., Taylor, E., Ng, V., Murrell, A., Patil, A., van der Touw, T., Sigal, R., Wolden, M., & Smart, N. (2022) · British Journal of Sports Medicine · doi:10.1136/bjsports-2021-103999 · Cited by 45
Kurogi, K., Sugiyama, S., Sakamoto, K., Tayama, S., Nakamura, S., Biwa, T., Matsui, K., & Ogawa, H. (2013) · Journal of Cardiology · doi:10.1016/j.jjcc.2013.03.008 · Cited by 42
Comparison of Preventive Effect on Cardiovascular Events With Different Statins - The CIRCLE Study -
Maruyama, T., Takada, M., Nishibori, Y., Fujita, K., Miki, K., Masuda, S., Horimatsu, T., & Hasuike, T. (2011) · Circulation Journal · doi:10.1253/circj.cj-10-1163 · Cited by 42
The potential role of statins in preeclampsia and dyslipidemia during gestation: a narrative review
Maierean, S. M., Mikhailidis, D. P., Toth, P. P., Grzesiak, M., Mazidi, M., Maciejewski, M., & Banach, M. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1465927 · Cited by 47
Ahn, J., Kim, Y., Chae, H., Choi, Y. H., Ahn, H., Yoo, H., Kang, M., Kim, J., & Chin, Y. (2019) · Journal of Natural Products · doi:10.1021/acs.jnatprod.8b00748 · Cited by 45
HDL—A molecule with a multi-faceted role in coronary artery disease
Arora, S., Patra, S. K., & Saini, R. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.10.021 · Cited by 52
Lipid Management in Chronic Kidney Disease: Systematic Review of PCSK9 Targeting
Zheng-Lin, B., & Ortíz, A. (2018) · Drugs · doi:10.1007/s40265-017-0858-2 · Cited by 41
Uydu, H. A., Yıldırmış, S., Örem, C., Calapoğlu, M., Alver, A., Kural, B. V., & Örem, A. (2012) · The Journal of Membrane Biology · doi:10.1007/s00232-012-9441-7 · Cited by 39
“The effects of statins on HDL-C levels have been controversial.”
InfluentialAtherogenic Index of Plasma in Obstructive Sleep Apnoea
Bikov, A., Mészáros, M., Kunos, L., Negru, A. G., Frent, S., & Mihaicuta, S. D. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10030417 · Cited by 42
“Apart from lowering total cholesterol, they may elevate HDL-C concentrations; however, this effect differs between drugs [35].”
BackgroundChae, H., You, B. H., Kim, D.-Y., Lee, H., Ko, H. W., Ko, H., Choi, Y. H., Choi, S. S., & Chin, Y. (2018) · Scientific Reports · doi:10.1038/s41598-018-24935-6 · Cited by 37
An update on efflux and uptake transporters as determinants of statin response
Rocha, K. C. E., Pereira, B. M. V., & Rodrigues, A. C. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1482276 · Cited by 42
“reduction, have shown a neutral or small effect on HDL cholesterol levels [123], which is an independent predictor of risk for cardiovascular events in patients who have been treated”
BackgroundMaxwell, K. F., Wahls, T. L., Browne, R. W., Rubenstein, L. M., Bisht, B., Chenard, C. A., Snetselaar, L., Weinstock‐Guttman, B., & Ramanathan, M. K. (2019) · PLoS ONE · doi:10.1371/journal.pone.0218075 · Cited by 38
Lipid efflux mechanisms, relation to disease and potential therapeutic aspects
Castaño, D., Rattanasopa, C., Monteiro-Cardoso, V. F., Corlianò, M., Liu, Y., Zhong, A., Rusu, M., Liehn, E. A., & Singaraja, R. R. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.04.013 · Cited by 38
Orsoni, A., Thérond, P., Tan, R., Giral, P., Robillard, P., Kontush, A., Meikle, P. J., & Chapman, M. J. (2016) · Journal of Lipid Research · doi:10.1194/jlr.p068585 · Cited by 40
Emerging therapies in Friedreich’s Ataxia
Zesiewicz, T. A., Hancock, J. U., Ghanekar, S. D., Kuo, S., Dohse, C. A., & Vega, J. (2020) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2020.1821654 · Cited by 45
Novel Therapies Focused on the High-Density Lipoprotein Particle
van Capelleveen, J. C., Brewer, H. B., Kastelein, J. J. P., & Hovingh, G. K. (2014) · Circulation Research · doi:10.1161/circresaha.114.301804 · Cited by 37
“There is controversy concerning the effect of this HDL-C increase on CVD outcome data,(24,25) and this might be related to the differences in HDL-C levels at baseline in these studies because it has been suggested that only patients with low HDL-C baseline values benefit from the statin-induced HDL-C increase.(23,26,2…”
BackgroundResultTargeting High-density Lipoproteins to Reduce Cardiovascular Risk: What Is the Evidence?
Barter, P. J., & Rye, K. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.07.021 · Cited by 35
Self-citationHigh Density Lipoprotein: A Therapeutic Target in Type 2 Diabetes
Barter, P. J. (2013) · Endocrinology and Metabolism · doi:10.3803/enm.2013.28.3.169 · Cited by 37
Self-citationZhang, L., Zhang, S., Yu, Y., Jiang, H., & Ge, J. (2018) · Herz · doi:10.1007/s00059-018-4767-2 · Cited by 42
“The VOYAGER meta-analysis also reported a 4–7% greater degree of lowering of all atherogenic lipids [11, 12].”
BackgroundResultToyama, K., Sugiyama, S., Oka, H., Iwasaki, Y., Sumida, H., Tanaka, T., Tayama, S., Jinnouchi, H., Matsui, K., & Ogawa, H. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.02.050 · Cited by 34
The Effects of Statin Medications on Aerobic Exercise Capacity and Training Adaptations
Murlasits, Z., & Radak, Z. O. (2014) · Sports Medicine · doi:10.1007/s40279-014-0224-4 · Cited by 34
“Thus, in light of the observation that the impact of statins on HDL-C is type and dose dependent [40], exercise could serve as an invaluable adjuvant therapy.”
BackgroundPel, P., Chae, H., Nhoek, P., Woojin, Y., Kim, Y., & Chin, Y. (2017) · Phytochemistry · doi:10.1016/j.phytochem.2017.01.010 · Cited by 31
“One of the statins, atorvastatin, was reported to increase both PCSK9 and LDL-R, but it was suggested that PCSK9 increment might lead to LDL-R degradation, resulting in ineffectiveness of statins in achieving the LDL-C control in some patients with familial hypercholesterolemia (Barter et al., 2010).”
BackgroundInfluentialOng, K. L., Wu, B. J., Cheung, B. M. Y., Barter, P. J., & Rye, K. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.07.094 · Cited by 30
“Statins vary in their ability to lower LDL cholesterol and raise HDL cholesterol [26,27].”
BackgroundResultSelf-citationHigh‐Density Lipoprotein Cholesterol Concentration and Acute Kidney Injury After Cardiac Surgery
Smith, L. E., Smith, D. K., Blume, J. D., Linton, M. F., & Billings, F. T. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.006975 · Cited by 34
Maejima, T., Tomohiro, S., Yamazaki, H., Yoshinaka, Y., Doi, T., Tanabe, S., & Nishimaki‐Mogami, T. (2011) · Journal of Pharmacological Sciences · doi:10.1254/jphs.10241fp · Cited by 32
Lipids and cardiovascular disease: where does dietary intervention sit alongside statin therapy?
Megson, I. L., Whitfield, P. D., & Zabetakis, I. (2016) · Food & Function · doi:10.1039/c6fo00024j · Cited by 34
A role for Apolipoprotein A-I in the pathogenesis of multiple sclerosis
Meyers, L., Groover, C. J., Douglas, J., Lee, S., Brand, D., Levin, M. C., & Gardner, L. A. (2014) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2014.10.010 · Cited by 27
Effects of Established Hypolipidemic Drugs on HDL Concentration, Subclass Distribution, and Function
Gomaraschi, M., Adorni, M. P., Banach, M., Bernini, F., Franceschini, G., & Calabresi, L. (2014) · Handbook of experimental pharmacology · doi:10.1007/978-3-319-09665-0_19 · Cited by 29
“Statin-induced changes in HDL-C are normally paralleled by an increase in apoA-I levels (Barter et al. 2010).”
BackgroundAbbas, A., Milles, J. J., & Ramachandran, S. (2012) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.4137/cmed.s7591 · Cited by 34
A method to estimate the contribution of rare coding variants to complex trait heritability
Pathan, N., Deng, W. Q., Scipio, M. D., Khan, M. D., Mao, S., Morton, R. W., Lali, R., Pigeyre, M., Chong, M., & Paré, G. (2024) · Nature Communications · doi:10.1038/s41467-024-45407-8 · Cited by 26
Kim, Y., Yoon, S., Choi, Y., Yoon, S. H., Cho, J., Jang, I., Yu, K., & Chung, J. (2019) · Scientific Reports · doi:10.1038/s41598-019-55562-4 · Cited by 28
Liu, J., Yang, T.-Y., Hsu, Y.-P., Hao, W., Kao, P., Sung, L., Chen, C., & Wu, S. (2016) · Oncotarget · doi:10.18632/oncotarget.11162 · Cited by 30
“For example, simvastatin and rosuvastatin increase HDL-C levels as their doses are increased, whereas at higher doses, atorvastatin attenuates increases in HDL-C levels [48].”
Evaluating computational models of cholesterol metabolism
Paalvast, Y., Kuivenhoven, J. A., & Groen, A. K. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2015.05.008 · Cited by 29
“Upon high baseline HDL-cholesterol levels however (> 50mg/dl), HDL-cholesterol has not been shown to increase further upon statin treatment [40].”
BackgroundManaging dyslipidemia in patients with Type 2 diabetes
Tomlinson, B., Patil, N. G., Fok, M., & Lam, C. W. K. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1912734 · Cited by 32
“triglyceride levels [45] and they are usually associated with a small increase in HDL-C which may be greater in patients with T2DM, high triglycerides, or lower baseline HDL-C [46].”
BackgroundPrevalence, patterns and determinants of dyslipidaemia among South African adults with comorbidities
Masilela, C. M., Adeniyi, O. V., & Benjeddou, M. (2022) · Scientific Reports · doi:10.1038/s41598-021-04150-6 · Cited by 27
Neurological aspects of SARS-CoV-2 infection: lipoproteins and exosomes as Trojan horses
Lam, S. M., Huang, X., & Shui, G. (2022) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2022.04.011 · Cited by 25
“Can conventional plasma lipid indices (e.g., HDL-C) and/or plasma levels of metabolites/lipids that originate primarily from the CNS (e.g., 24-OHC) serve as early prognostic indicators of neurological outcome in patients with COVID-19?”
InfluentialKim, J., Kim, M. K., Baek, K., Song, K., Han, K., & Kwon, H. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2021.1332 · Cited by 25
Ptchd1 mediates opioid tolerance via cholesterol-dependent effects on μ-opioid receptor trafficking
Maza, N. A., Wang, D., Kowalski, C. W., Stoveken, H. M., Dao, M. T., Sial, O. K., Giles, A. C., Grill, B. J., & Martemyanov, K. A. (2022) · Nature Neuroscience · doi:10.1038/s41593-022-01135-0 · Cited by 24
Pitavastatin and HDL: Effects on plasma levels and function(s)
Pirillo, A., & Catapano, A. L. (2017) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2017.05.001 · Cited by 26
Li, X., Guo, Y., Zhu, C., Xu, R., Qing, P., Wu, N., Jiang, L., Xu, B., Gao, R., & Li, J. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.114.001412 · Cited by 26
“The HDL-C-increasing effect of statins is caused by inhibition of cholesteryl ester transfer protein activity,(38,39) and is unrelated to changes in LDL-C by statins.(40) Whether the loss of relation of HDL-C and cardiovascular risk in intensive statin therapy can be explained by functional changes in HDL during inten…”
BackgroundMa, Y.-B., Chan, P., Zhang, Y., Tomlinson, B., & Liu, Z. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1594776 · Cited by 23
“Other analyses have shown that the HDL-C raising ability of atorvastatin is less than with rosuvastatin or simvastatin [21,22].”
BackgroundInclisiran—Silencing the Cholesterol, Speaking up the Prognosis
Rogula, S., Błażejowska, E., Gąsecka, A., Szarpak, Ł., Jaguszewski, M. J., Mazurek, T., & Filipiak, K. J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112467 · Cited by 27
“On the other hand, statins reduce triglyceride [106] and increase HDL cholesterol levels [107], whereas a 300-mg dose of inclisiran showed no significant difference with regard to HDL-C and triglyceride levels [108].”
BackgroundZambrano, T., Hirata, R. D. C., Hirata, M. H., Cerda, Á., & Salazar, L. A. (2015) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-015-6627-0 · Cited by 23
“Therefore, atorvastatin, which raises THP-1 miR-33 expression, accordingly diminishes ABCA1 expression and ABCA1-mediated cholesterol efflux, abrogating the increased HDL-C benefit of CETP inhibitors, which is highly important taking into account previous data showing repressed expression of both ABCA1 and ABCG1 chole…”
ResultInfluentialMass spectrometry-based approaches to targeted quantitative proteomics in cardiovascular disease
Mesaros, C., & Blair, I. A. (2016) · Clinical Proteomics · doi:10.1186/s12014-016-9121-1 · Cited by 27
“Although, there is clear evidence that up-regulation of PPARα by statins results in increased ApoA-I, there is a curious discrepancy on the reported efficacy of different statins [24].”
InfluentialAlsayed, N., Almahmeed, W. A., Alnouri, F., Al-Waili, K., Sabbour, H. M., Sulaiman, K., Zubaid, M., Ray, K. K., & Al‐Rasadi, K. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.11.022 · Cited by 25
Karlson, B. W., Nicholls, S. J., Lundman, P., Palmer, M. K., & Barter, P. J. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.02.027 · Cited by 24
“The VOYAGER individual patient data meta-analysis has been described in detail previously [11,12].”
Self-citationBener, A., Dogan, M., Barakat, L., & Al-Hamaq, A. A. A. (2014) · Indian Journal of Pharmacology · doi:10.4103/0253-7613.125184 · Cited by 22
“[7] Statins are considered the first line pharmacological treatment of dyslipidemia in diabetic patients.”
InfluentialCurrent perspectives on rosuvastatin
Tomlinson, B., & Hu (2013) · Integrated Blood Pressure Control · doi:10.2147/ibpc.s34814 · Cited by 26
“The change in HDL-C with statins was independent of LDL-C change, but was influenced by baseline HDL-C and triglyceride levels and the presence of diabetes.(29) It has been reported that rosuvastatin at different doses sig-”
Statins in cardiometabolic disease: what makes pitavastatin different?
Ginsberg, H. N. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-s1-s1 · Cited by 25
“Although most statins increase HDL-C levels to some extent, pitavastatin consistently produces signifi cantly greater HDL elevations that are maintained, or increased, over time [29,58,60,62-64].”
BackgroundMauschitz, M. M., Verzijden, T., Schuster, A. K.-G., Elbaz, H., Pfeiffer, N., Khawaja, A. P., Luben, R., Foster, P. J., Rauscher, F. G., Wirkner, K., et al. (2022) · British Journal of Ophthalmology · doi:10.1136/bjo-2022-321985 · Cited by 22
“[58, 59] 35 Lastly, while statins have a safe side effect profile, rare and serious adverse reactions such 36 as rhabdomyolysis can occur and statin therapy needs to be monitored by physicians.”
BackgroundGalović, R., Flegar-Meštrić, Z., Vidjak, V., Matokanović, M., & Barišić, K. (2015) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2015.10.006 · Cited by 21
“Although generally expected to be slightly increased from its basic level due to the statin therapy [17], levels of HDL cholesterol were still lower in cerebrovascular atherosclerosis than in the control group, confirming lower HDL cholesterol as a well known risk factor.”
BackgroundSex disparities in the effect of statins on lipid parameters: The PharmLines Initiative
Hunt, N. B., Emmens, J. E., Irawati, S., de Vos, S., Bos, J. H. J., Wilffert, B., Hak, E., & de Boer, R. A. (2022) · Medicine · doi:10.1097/md.0000000000028394 · Cited by 22
“Low baseline HDL-C and high baseline TG were found as independent predictors of a higher percentage change of HDL-C from baseline for atorvastatin, rosuvastatin, and simvastatin.([27,28]) Women in our study had a higher baseline HDL-C and a lower baseline TG compared tomen, yet they still demonstrated a greater HDL-C…”
BackgroundResultInfluentialProtective effects of statins on the incidence of NAFLD –related decompensated cirrhosis in T2DM
Wu, S., Chen, W., Chiang, M., Lo, H., Wu, M., Lee, M., & Soong, R. (2023) · Liver International · doi:10.1111/liv.15656 · Cited by 21
of the DISSEMINATE study group, Selvaraj, F. J., Mohamed, M., Omar, K., Nanthan, S., Kusiar, Z., Subramaniam, S. Y., Ali, N., Karanakaran, K., Ahmad, F., et al. (2012) · BMC Family Practice · doi:10.1186/1471-2296-13-97 · Cited by 20
“This finding was inconsistent with many clinical studies that reported mild improvement of HDL-C with both drug treatment and disease management care [25,26].”
ResultTo study the effect of high dose Atorvastatin 40 mg versus 80 mg in patients with dyslipidemia
Agrawal, D. K., Manchanda, S. C., Sawhney, J. P. S., Kandpal, B., Jain, R., Mehta, A., Mohanty, A. K., Passey, R., Makhija, A., & Sharma, M. K. (2018) · Indian Heart Journal · doi:10.1016/j.ihj.2018.01.034 · Cited by 18
“3% increase in serum HDL cholesterol with 80 mg dose of atorvastatin.(14) It was concordant with our study which showed percentage increase in HDL-Cholesterol in the range of 9.”
ResultLi, W., Sultana, N., Yuan, L. X. H., Forssell, C., & Yuan, X. (2022) · Metabolites · doi:10.3390/metabo12010054 · Cited by 18
“It is well known that one of the cardiovascular benefits of statin is to raise HDL levels [27].”
BackgroundPresent and Future of Dyslipidaemia Treatment—A Review
Merćep, I., Vujević, A., Strikić, D., Radman, I. B., Pećin, I., & Reiner, Ž. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12185839 · Cited by 25
“Statin use is associated with a moderate increase in HDL-C levels and a decrease in triglyceride (TG)levels, with simvastatin and rosuvastatin achieving better results than atorvastatin for these lipids and lipoproteins [17].”
BackgroundZieliński, K., Kalińczuk, Ł., Chmielak, Z., Mintz, G. S., Dąbrowski, M., Pręgowski, J., Świerczewski, M., Kowalik, I., Demkow, M., Hryniewiecki, T., et al. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.03.037 · Cited by 20
Hasvold, P., Thuresson, M., Sundström, J., Hammar, N., Kjeldsen, S. E., Johansson, G., Holme, I., & Bodegård, J. (2015) · Clinical Drug Investigation · doi:10.1007/s40261-015-0372-9 · Cited by 20
“level [10] may have a suboptimal balance of cholesterol in/ out transport to/from the inner arterial wall.”
BackgroundResultInfluential
Metadata
- Authors
- Barter, P. J., Brandrup-Wognsen, G., Palmer, M. K., & Nicholls, S. J.
- Affiliations
- The Heart Research Institute (AU)
- Keele University (GB)
- Cleveland Clinic (US)
- Corresponding author
- Barter, Philip J.
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 2010-06
- Volume
- 51
- Issue
- 6
- Pages
- 1546-1553
- ISSN
- 0022-2275 (ISSN-L)
- PMC
- PMC3035518
- OpenAlex
- W2134105637
- Cited by
- 259
- References
- 38
- Citations by year
- 2026: 12 · 2025: 18 · 2024: 16 · 2023: 23 · 2022: 11 · 2021: 19 · 2020: 17 · 2019: 8 · 2018: 16 · 2017: 11 · 2016: 15 · 2015: 15 · 2014: 23 · 2013: 15 · 2012: 13
- FWCI
- 13.49
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 3790 d)
- Locations
- Journal of Lipid Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- statins, HDL cholesterol, LDL cholesterol, rosuvastatin, atorvastatin, simvastatin, apolipoprotein A-I, triglycerides, diabetes mellitus, dyslipidemia, statin dose
- MeSH terms
- Adolescent, Adult, Aged, Dose-Response Relationship, Drug, Female, Humans, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Triglycerides, Randomized Controlled Trials as Topic, Databases, Factual, Apolipoprotein A-I, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.